Kemwell Biopharma increases biologies manufacturing capacity

摘要

Kemwell Biopharma, a biologies CDMO, has recently augmented its existing infrastructure. As part of this, the company has installed Ambr 250, high throughput equipment with 12 automated mini bioreactors at a 250 ml scale to accelerate process development. Ambr 250 enables setting of 12 different media conditions, temperatures and gases, helping the client projects identify optimal processes for higher titers while reducing the cost per experiment. The company is exploring strategic partnerships with biopharma players in the surrounding ecosystem to fit out this additional capacity.